Booster Vaccination Study to Assess Immunogenicity and Safety of a Dose of GSK Biologicals Mencevax ACWY and 1/5th of a Dose of Mencevax ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study [EXTENSION OF 700037923].

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hib-DTP-hepatitis B vaccine (Primary) ; Meningococcal vaccine groups A C W-135 polysaccharide; Meningococcal vaccine groups A C Y W-135 polysaccharide
Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Pertussis; Tetanus
Focus Pharmacodynamics
Sponsors GlaxoSmithKline; GSK

Most Recent Events

05 May 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight